David Herthnek

David Herthnek (CSO) holds a MSc in Biotechnology from Linköping University and completed his PhD in Molecular Biology on diagnostic method development at the Swedish National Veterinary Institute. David started his career as a researcher and worked for seven years at Uppsala University and Stockholm University, exploring the field of padlock probes for IVD (in vitro diagnostics) development for clinical applications. Here, he improved method application of padlock probes for detection of multi drug resistant (MDR) and extensively resistant (XDR) tuberculosis (TB) strains, and played vital role in the development of multiplex tests for various disease pathogen panels, including highly infectious viruses like ebola, zika and dengue. David has extensive experience of handling various national and international projects and contributed in the development of automated instruments. He has supervised PhD and master thesis students and published more than 15 research articles in the area of molecular diagnostics. Together with the founders of EMPE Diagnostics, David has co-authored the research article of combining padlock probe-dependent rolling circle amplification and sensitive lateral flow technology for the detection of multi drug resistant tuberculosis (MDR-TB), which is the core idea of the company.

For four years, he has gained experience from the IVD industry in the position as Technical Project Lead for NPI (New Product Introduction) projects at Cepheid, a globally leading developer of fully automated molecular tests and instruments. There, he led the development of HIV tests from concept to launch of WHO-endorsed CE-IVD products. David brings his industrial regulatory experience combined with scientific project management skills to EMPE.